We have located links that may give you full text access.
Comparative Study
Journal Article
Meta-Analysis
Review
Carotid Artery Endarterectomy versus Carotid Artery Stenting for Restenosis After Carotid Artery Endarterectomy: A Systematic Review and Meta-Analysis.
World Neurosurgery 2018 July
OBJECTIVE: Carotid artery restenosis may occur after ipsilateral carotid endarterectomy (CEA). The aim of this study was to determine whether carotid artery stenting (CAS) or redo CEA is the optimal treatment for postendarterectomy carotid restenosis.
METHODS: Eligible studies for meta-analysis were identified through a search of PubMed, Scopus, and Cochrane up to July 20, 2017. A meta-analysis was conducted with the use of random effects modeling. I2 was used to assess for heterogeneity.
RESULTS: Thirteen studies comprising 4163 patients were included. Risk for any type of cranial nerve injury was higher in the redo CEA group (odds ratio = 13.61; 95% confidence interval, 5.43-34.16; I2 = 3.3%). Periprocedural and/or short-term (within 30 days) stroke, transient ischemic attack, myocardial infarction, temporary cranial nerve injury, and death rates were similar between the 2 revascularization approaches. During median follow-up of 28 months, CAS was associated with significantly lower risk for long-term recurrent carotid artery restenosis when defined as stenosis >60% (odds ratio = 2.16; 95% confidence interval, 1.13-4.12; I2 = 0%) or >70% (odds ratio = 2.31; 95% confidence interval, 1.13-4.72; I2 = 0%). No difference was identified in long-term target lesion revascularization rates between redo CEA and CAS.
CONCLUSIONS: Patients with carotid restenosis after CEA can safely undergo both CAS and CEA with similar risks of periprocedural stroke, transient ischemic attack, myocardial infarction, and death. However, patients treated with CAS have a lower risk for a new restenosis and periprocedural cranial nerve injury.
METHODS: Eligible studies for meta-analysis were identified through a search of PubMed, Scopus, and Cochrane up to July 20, 2017. A meta-analysis was conducted with the use of random effects modeling. I2 was used to assess for heterogeneity.
RESULTS: Thirteen studies comprising 4163 patients were included. Risk for any type of cranial nerve injury was higher in the redo CEA group (odds ratio = 13.61; 95% confidence interval, 5.43-34.16; I2 = 3.3%). Periprocedural and/or short-term (within 30 days) stroke, transient ischemic attack, myocardial infarction, temporary cranial nerve injury, and death rates were similar between the 2 revascularization approaches. During median follow-up of 28 months, CAS was associated with significantly lower risk for long-term recurrent carotid artery restenosis when defined as stenosis >60% (odds ratio = 2.16; 95% confidence interval, 1.13-4.12; I2 = 0%) or >70% (odds ratio = 2.31; 95% confidence interval, 1.13-4.72; I2 = 0%). No difference was identified in long-term target lesion revascularization rates between redo CEA and CAS.
CONCLUSIONS: Patients with carotid restenosis after CEA can safely undergo both CAS and CEA with similar risks of periprocedural stroke, transient ischemic attack, myocardial infarction, and death. However, patients treated with CAS have a lower risk for a new restenosis and periprocedural cranial nerve injury.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app